# A Study of Baricitinib and Rifampicin in Healthy Participants

> **NCT01910311** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 18 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT01910311
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910311, "A Study of Baricitinib and Rifampicin in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01910311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*